Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Evommune, Inc. (NASDAQ:EVMN) shares are trading lower on Thursday on profit-taking after the stock soared around 70% on Wednesday.On Tuesday, the company shared positive results from its Phase 2a trial evaluating EVO301 for treating moderate-to-severe atopic dermatitis.EVO301 Trial Shows 33% Improvement in EASIIn the recent trial, Evommune reported a 33% placebo-adjusted improvement in the Eczema Area and Severity Index (EASI) at week 12, with 23% of patients achieving a score of 0 or 1 on the Investigator' ...